HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure.

AbstractOBJECTIVE:
To study the haemodynamic profile and tolerability of imidapril, a new long-acting ACE inhibitor, and to investigate the effect of inhibition of circulating ACE on blood pressure in patients with stable chronic heart failure.
METHODS:
Twenty-four patients with stable, chronic heart failure (New York Heart Association (NYHA) functional Class II-III) were randomised to receive either 2.5 mg or 5 mg imidapril. Other vasodilators were withheld for > or = 5 half-lives. Blood pressure and ACE activity were carefully monitored for 24 h after dosing.
RESULTS:
Both 2.5 mg and 5 mg imidapril decreased systolic blood pressure, while diastolic blood pressure fell only after 5 mg imidapril. The two doses produced a significant and similar inhibition of circulating (serum) ACE. No serious adverse effects were observed, although symptomatic hypotension occured in 1 patient (5 mg). The decrease in blood pressure was not related to baseline ACE activity, serum sodium or serum creatinine concentration.
CONCLUSIONS:
Imidapril significantly lowered systolic blood pressure and was well tolerated. The difference in the first dose response to the two doses with respect to diastolic blood pressure suggests that this haemodynamic effect of ACE-inhibition is not related to inhibition of circulating ACE.
AuthorsY M Pinto, D J van Veldhuisen, R T Tjon-Ka-Jie, G Rooks, T Netzer, K I Lie
JournalEuropean journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 50 Issue 4 Pg. 265-8 ( 1996) ISSN: 0031-6970 [Print] Germany
PMID8803516 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Imidazoles
  • Imidazolidines
  • imidapril
Topics
  • Administration, Oral
  • Aged
  • Analysis of Variance
  • Angiotensin-Converting Enzyme Inhibitors (administration & dosage)
  • Antihypertensive Agents (administration & dosage)
  • Blood Pressure (drug effects)
  • Chronic Disease
  • Double-Blind Method
  • Female
  • Heart Failure (drug therapy)
  • Humans
  • Imidazoles (administration & dosage)
  • Imidazolidines
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: